As of November 10, 2026, Eloxx Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: ELOX); its largest reported holder is Domicilium Capital Partners LLC, with 19.99% on Schedule 13G of June 17, 2026, then Coastlands Capital LP (9.99%). The largest insider holding is Sumit Aggarwal, the chief executive and president, with 1,672,756 shares (41.4% of shares outstanding), per Form 4 of May 8, 2026 (Schedule 13G, June 17, 2026).
Is this your company?
About to sign with, pay or invest in Eloxx Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Eloxx Pharmaceuticals, Inc. a real, registered company?
- Eloxx Pharmaceuticals, Inc. files with the SEC under CIK 1035354 (its SEC filings).
- Its shares are listed under the ticker ELOX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Arlington, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Eloxx Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Leadership changes: the latest reported is Geno J. Germano, Director (Form 8-K filed 2026-10-22). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Srinivas Akkaraju (filed 2026-08-14).
Who are Eloxx Pharmaceuticals, Inc.'s owners and officers?
Eloxx Pharmaceuticals, Inc.: incorporated in Delaware; business address in Arlington, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-10-22).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | Srinivas Akkaraju | 9.9% |
| Schedule 13G, 2026-08-14 | Nantahala Capital Management, LLC | 9.91% |
| Schedule 13G, 2026-07-27 | Aberdeen Group PLC | 9.91% |
| Schedule 13G, 2026-06-17 | Domicilium Capital Partners LLC | 19.99% |
| Schedule 13G, 2026-06-17 | Coastlands Capital LP | 9.99% |
| Schedule 13G, 2026-06-16 | Ecor1 Capital, LLC | 9.9% |
| Schedule 13G, 2026-06-16 | Stonepine Capital Management, LLC | 9.9% |
| Schedule 13G, 2026-06-15 | Raymond Debbane | 9.99% |
| Schedule 13G/A, 2026-06-05 | Domicilium Capital Partners LLC | 4.9% |
| Schedule 13G/A, 2026-05-29 | Coastlands Capital LP | 4.99% |
| Schedule 13G, 2026-05-04 | Domicilium Capital Partners LLC | 18.6% |
| Schedule 13G, 2026-05-01 | Coastlands Capital LP | 16.51% |
Questions about who owns Eloxx Pharmaceuticals, Inc.
Who owns Eloxx Pharmaceuticals, Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of Eloxx Pharmaceuticals, Inc.: Domicilium Capital Partners LLC (19.99%, Schedule 13G, filed 2026-06-17), Coastlands Capital LP (9.99%, Schedule 13G, filed 2026-06-17), Raymond Debbane (9.99%, Schedule 13G, filed 2026-06-15), Nantahala Capital Management, LLC (9.91%, Schedule 13G, filed 2026-08-14) and Aberdeen Group PLC (9.91%, Schedule 13G, filed 2026-07-27); 3 more are listed above.
Who are the largest shareholders of Eloxx Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Eloxx Pharmaceuticals, Inc. on this page are Domicilium Capital Partners LLC (19.99%), Coastlands Capital LP (9.99%) and Raymond Debbane (9.99%).
When did Domicilium Capital Partners LLC buy into Eloxx Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Domicilium Capital Partners LLC on this page is the Schedule 13G, filed 2026-05-04, reporting 18.6%; its latest, Schedule 13G filed 2026-06-17, reports 19.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Eloxx Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Eloxx Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eloxx Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
25 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-22 | Geno J. Germano | Director | appointed | |
| Form 8-K, 2026-06-01 | Stephen W. Webster | Director | appointed |
Which insiders own Eloxx Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 1,672,756 shares (41.4% of shares outstanding) (Form 4, 2026-05-08).
- Domicilium Real Estate Fund III LP, a 10% owner: 361,578 shares (9.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-06-17).
- , a director: 15,750 shares (0.39% of shares outstanding) (Form 4, 2025-01-28).
- , a director: 15,567 shares (0.39% of shares outstanding) (Form 4, 2026-05-08).
- , a director: 14,625 shares (0.36% of shares outstanding) (Form 4, 2026-05-08).
Shares outstanding: 4,036,459 as of 2026-08-07, from the company's latest SEC cover page.
How much has Eloxx Pharmaceuticals, Inc. raised?
Latest IPO step: Eloxx Pharmaceuticals, Inc. filed to go public (S-1, 2026-09-11).
IPO filings: S-1, 2026-09-11, 424B4, 2026-06-09, S-1/A, 2026-06-04, S-1/A, 2026-06-01, S-1, 2026-05-07; ticker ELOX on Nasdaq Capital Market.
Keep reading
More on Eloxx Pharmaceuticals, Inc. and the records around it.
Eloxx Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Jun 2026
Companies that share a holder
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026), KALARIS THERAPEUTICS, INC. (May 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/eloxx-pharmaceuticals